A pharmaceuticals company that raised the price of a drug 5,500% practically overnight says it will now lower its price following intense backlash.
Turing Pharmaceuticals founder Martin Shkreli confirmed the price cut to NBC News on Tuesday but did not say how much the company would reduce the cost of Daraprim.
Early this week, Turing’s decision to raise the price of Daraprim from $13.50 a tablet to $750 was the subject of a New York Times story. The drug, which is generically known as pyrimethamine and was acquired by the company acquired in August, is used to treat a serious parasitic infection called toxoplasmosis, which can be life-threatening for those with compromised immune systems. It’s also been used to treat malaria.
Shkreli said the new price will allow the company to break even or make a “small profit” on the drug.
- The Case for Mediocrity
- How Russia Is Recruiting Cubans to Fight in Ukraine
- Paul Hollywood Answers All of Your Questions About The Great British Baking Show
- Meet the 2023 TIME100 Next: the Emerging Leaders Shaping the World
- Oprah and Arthur C. Brooks: How to Separate Work From Your Identity
- How Canada and India's Relationship Crumbled
- You Don’t Have to Like Wrestling to Love Netflix’s Excellent Wrestlers
- The Most Anticipated Books, Movies, TV, and Music of Fall 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time